17 Jan 2013, BioSpectrum Bureau , BioSpectrum
Bangalore: During the past several years, biosimilars has been drawing the market's attention due to the upcoming patent cliff. There is an increasing interest in the development of follow-on protein products in light of advances in manufacturing technology, process control and protein characterization.
Leading organizations such as Wockhardt, Zydus Cadila, Indian Immunologicals, Biological E, Lupin, Reliance Life Sciences, Serum Institue of India, Bharat Serums and Vaccines are now focusing their resources on the critical aspects of process development and analytics to ensure successful commercialization of their products in the near future.
Dr Anurag Rathore, IIT Delhi, who is expected to speak at the 4th Annual Biosimilars conference taking place from March 6-8, 2013, at Mumbai, India, will discuss how to use Process Analytical Technology (PAT) for designing and controlling the development process of biologics.
Dr Ajaz Hussain , president and CSO Biotechnology, Wockhardt; Dr MK Sahib, director genomics and biotechnology, Wockhardt; and Dr Anand Kumar, deputy managing director, India Immunologics; will also be addressing key issues revolving around regulatory updates in analytical and process development, platform technologies in upstream and impurity profiling in downstream, physiochemical and biological characterization and up-scaling for production.
Mr Orlando Vitor Silva and Mr Allan Riting Liu will be evaluating emergence of countries like Brazil, Argentina, Venezuela and Mexico, to develop calculated strategies to capitalise these markets during the post conference workshop of Commericialization of Biosimilars. With the continuously evolving landscape of biosimilars in India, some good discussions can be expected to emerge out of these presentations.